Project Grant R01CA299937
Award Date 7/10/26
Completion Date 5/31/31
Dollars Obligated $586K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Charleston, SC 29425, USA
Similar Awards
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded the University of Southern California $426,828 on July 6, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to conduct a two-year research project concluding June 30, 2028. This project will test innovative regulatory strategies to promote e-cigarette cessation among young adults through controlled experimental research in a simulated vape retail environment called "The Puff Point."...
- Federal Grant Award Summary The National Cancer Institute (NCI), under the Cancer Cause and Prevention Research program (CFDA 93.393), awarded the University of Alabama a Project Grant of $2,524,071 on September 23, 2025, for research investigating the neurocomputational mechanisms underlying self-regulation and reinforcement learning in smoking cessation decisions. The four-year project, with completion scheduled for August 31, 2029, will employ computational model-based multimodal neuroimaging...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded the University of Pennsylvania a Project Grant of $663,554 under the Cancer Cause and Prevention Research program (CFDA 93.393) on August 18, 2025, with an ultimate completion date of July 31, 2030. This research project, titled "Catalyzing Cigarette Smoking Cessation Through Harm Reduction Sampling Among People Unmotivated to Quit," will develop and test harm reduction product sampling as a pragmatic...
- Grant Award Summary Duke University received a $906,306 Project Grant from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) awarded September 11, 2025, with completion targeted for August 31, 2028. The award funds development and testing of a telehealth-delivered, cue-based treatment intervention designed to promote smoking cessation among people who smoke lightly (PSLI), defined as those smoking 10 cigarettes per day or fewer. Building...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded the University of Pittsburgh a $2.2 million Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) on August 7, 2025, with a completion date of July 31, 2029. This basic experimental study with humans addresses smoking cessation and craving by investigating dyadic processes between romantic partners and smoking friends. The research integrates theoretical and methodological approaches from...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Virginia Polytechnic Institute & State University a $395,248 Project Grant effective August 11, 2025, under the Cancer Cause and Prevention Research program (CFDA 93.393) to conduct proof-of-concept and feasibility testing of episodic future thinking (EFT) interventions for smoking cessation. This two-year project, concluding July 31, 2027, will develop and evaluate both generalized EFT and cancer-specific EFT approaches...
- Federal Project Grant Award Summary Wake Forest University Health Sciences received a $473,071 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective January 1, 2026, through December 31, 2028. The award funds research investigating the molecular mechanisms by which nicotine promotes brain metastasis in lung cancer patients by activating GABAergic (gamma-aminobutyric acid-releasing) neurons. The research will elucidate the...
- Federal Project Grant Award Summary Cincinnati Children's Hospital Medical Center received a $694,182 Project Grant from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393), awarded June 1, 2026, with completion targeted for May 31, 2031. This five-year prospective cohort study will enroll 300 children ages 1-10 years across three exposure groups—exclusive electronic cigarette (EC) users, exclusive combustible cigarette (CC) smokers, and no...
- Grant Award Summary The National Cancer Institute (NCI) awarded Mayo Clinic $823,878 on September 4, 2025, under the Cancer Treatment Research program (CFDA 93.395) to conduct a Phase II randomized, double-blind clinical trial evaluating vagal nerve stimulation (VNS) as a novel treatment for tobacco use disorder in conjunction with nicotine replacement therapy. The research will assess the efficacy of combining active VNS with nicotine patches over 12 weeks, with an additional 12-week phase of...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded $621,549 to the Regents of the University of Minnesota under the Cancer Cause and Prevention Research program (CFDA 93.393) for a five-year project beginning June 1, 2026, and concluding May 31, 2031. The research will evaluate the acceptability and substitutability of nicotine pouches—a non-combustible tobacco product category—as alternatives to menthol and non-menthol combustible cigarettes. This study addresses...